Abstract
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.
MeSH terms
-
Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
-
Agammaglobulinaemia Tyrosine Kinase / chemistry
-
Agammaglobulinaemia Tyrosine Kinase / metabolism*
-
Animals
-
Benzamides / chemistry
-
Benzamides / metabolism
-
Benzamides / pharmacology
-
Bridged Bicyclo Compounds, Heterocyclic / chemistry
-
Bridged Bicyclo Compounds, Heterocyclic / metabolism
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
-
Crystallography, X-Ray / methods
-
Dogs
-
Dose-Response Relationship, Drug
-
Drug Discovery / methods*
-
Female
-
Humans
-
Mice
-
Protein Binding / physiology
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / metabolism*
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Structure, Secondary
-
Protein Structure, Tertiary
-
Rats
-
Rats, Inbred Lew
-
Sheep
Substances
-
Benzamides
-
Bridged Bicyclo Compounds, Heterocyclic
-
CGI 1746
-
Protein Kinase Inhibitors
-
Agammaglobulinaemia Tyrosine Kinase
-
BTK protein, human